Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CURRENTS: Erlotinib 300 mg vs 150 mg in NSCLC smokers
NCT01183858Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2010
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Oct 2010; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01183858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01183858.